This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Achaogen (AKAO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Achaogen (AKAO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Achaogen (AKAO) Files for Bankruptcy, Shares Plunge 65%
by Zacks Equity Research
Achaogen (AKAO) files for bankruptcy in a district court. Shares slump 65% on the announcement.
Achaogen (AKAO) Upgraded to Buy: Here's Why
by Zacks Equity Research
Achaogen (AKAO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is the Options Market Predicting a Spike in Achaogen (AKAO) Stock?
by Zacks Equity Research
Investors need to pay close attention to Achaogen (AKAO) stock based on the movements in the options market lately.
Achaogen (AKAO) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Achaogen (AKAO) delivered earnings and revenue surprises of 8.33% and -47.44%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Is the Options Market Predicting a Spike in Achaogen (AKAO) Stock?
by Zacks Equity Research
Investors in Achaogen (AKAO) need to pay close attention to the stock based on moves in the options market lately.
New Strong Sell Stocks for August 7th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Achaogen (AKAO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Achaogen (AKAO) delivered earnings and revenue surprises of -30.43% and 71.95%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Options Traders Expect Huge Moves in Achaogen (AKAO) Stock
by Zacks Equity Research
Investors in Achaogen (AKAO) need to pay close attention to the stock based on moves in the options market lately.
Options Traders Expect Huge Moves in Achaogen (AKAO) Stock
by Zacks Equity Research
Investors in Achaogen (AKAO) need to pay close attention to the stock based on moves in the options market lately.
Achaogen's NDA for Plazomicin Gets Priority Review From FDA
by Zacks Equity Research
Achaogen's (AKAO) NDA for its urinary tract infections candidate, plazomicin, gets FDA's priority review.
Is the Options Market Predicting a Spike in Achaogen (AKAO) Stock?
by Zacks Equity Research
Investors in Achaogen (AKAO) need to pay close attention to the stock based on moves in the options market lately.
Achaogen's Plazomicin Gets Breakthrough Therapy Designation
by Zacks Equity Research
Achaogen, Inc. (AKAO) announced that the FDA granted Breakthrough Therapy designation for plazomicin, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae.
Fogo de Chao (FOGO) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Fogo de Chao, Inc. (FOGO) is set to report fourth-quarter and full-year 2016 results on Mar 14, after market close.
Achaogen (AKAO) Shares March Higher, Can It Continue?
by Zacks Equity Research
Achaogen, Inc. (AKAO) has been on the move lately as the stock has risen by 23.9% in the past four weeks, and it is currently trading well above its 20-Day SMA
Achaogen (AKAO) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Achaogen, Inc. (AKAO).
The Zacks Analyst Blog Highlights: CoLucid Pharmaceuticals, Exelixis, TESARO and Achaogen
by Zacks Equity Research
The Zacks Analyst Blog Highlights: CoLucid Pharmaceuticals, Exelixis, TESARO and Achaogen
4 Biotech Stocks that More than Doubled in 2016
by Arpita Dutt
Despite the immense pressure on the sector, there were some biotech stocks that bucked the trend and more than doubled in 2016.
Big Changes to BioShares Biotech ETFs: Who's In, Who's Out?
by Sanghamitra Saha
Inside the changes in portfolio constituents of two BioShares Biotech ETFs.
New Strong Buy Stocks for July 12th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday